Medicenna Therapeutics 주식 가격. MDNA - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

1.57

매수가

1.55

매도가

1.59

거래량

34,606

1.49 일간 변동폭 1.57

0.38 52주 범위 2.98

market_cap

109.33M

전일 종가

1.49

개장가

1.53

최근 거래 시간

1.57

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

82,428

발행 주식

69,637,000

배당수익률

주가수익률

-4.29

주당순이익(EPS)

-0.37

매출

순이익

-25.47M

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.medicenna.com

본부

Toronto, Ontario, Can

설립됨

Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the 토론토 증권거래소 with ticker MDNA. The last closing price for Medicenna Therapeutics was $1.49. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.38 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares in issue. The market capitalisation of Medicenna Therapeutics is $103.76 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -4.29.

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression...

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor...

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna...

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class...

Medicenna Announces Results of Annual Meeting of Shareholders

TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on...

Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference

MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and...

Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

TORONTO and HOUSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...

Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference

TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-0.12	-7.10059171598	1.69	1.71	1.27	93505	1.50838984	CS
4	-0.66	-29.5964125561	2.23	2.62	1.27	121595	1.96731176	CS
12	-0.53	-25.2380952381	2.1	2.62	1.27	82428	2.0635183	CS
26	-0.83	-34.5833333333	2.4	2.98	1.27	88319	2.13727884	CS
52	1.12	248.888888889	0.45	2.98	0.38	97328	1.79548736	CS
156	-1.15	-42.2794117647	2.72	2.98	0.215	62474	1.43677429	CS
260	-0.1	-5.9880239521	1.67	7.25	0.215	75084	2.75499225	CS

가장 활성
% 상승자
% 패자

기호	가격	볼륨
AABAberdeen International Inc	$ 0.065 (18.18%)	226.54k
MDPMedexus Pharmaceuticals Inc	$ 2.45 (15.02%)	46.31k
NCFNorthcliff Resources Ltd	$ 0.04 (14.29%)	5k
SAMStarcore International Mines Ltd	$ 0.16 (14.29%)	200k
GECGlobal Education Communities Corp	$ 0.225 (12.50%)	60k
BNGBengal Energy Ltd	$ 0.005 (-50.00%)	20k
RTGRTG Mining Inc	$ 0.03 (-25.00%)	13k
SMCSulliden Mining Capital Inc	$ 0.015 (-25.00%)	200k
APSAptose Biosciences Inc	$ 0.27 (-20.59%)	346.55k
FLNTFlint Corporation	$ 0.025 (-16.67%)	28k
SUSuncor Energy Inc	$ 58.04 (0.94%)	14.14M
MFCManulife Financial Corporation	$ 45.42 (-0.53%)	9.73M
SLFSun Life Financial Inc	$ 85.54 (-0.23%)	6.19M
BITFBitfarms Ltd	$ 2.96 (3.14%)	6.17M
CNQCanadian Natural Resources Ltd	$ 48.70 (0.83%)	4.91M